News >

Individualized Adjuvant Endocrine Approach Appropriate in Breast Cancer

Jason Harris
Published: Wednesday, Oct 25, 2017

breast cancer
Ten-year results from the TEAM trial showed that exemestane alone and sequential treatment with tamoxifen followed by exemestane are both “reasonable adjuvant treatment options” for postmenopausal women with hormone receptor-positive breast cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x